Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04402580|
Recruitment Status : Terminated (due to unexpectedly high rate of relapse in the active comparator arm.)
First Posted : May 27, 2020
Last Update Posted : September 14, 2020
Anti-CD20 monoclonal antibodies are emerging as the steroid-sparing therapy of choice for nephrotic syndrome.
This Randomized Clinical Trial seeks to evaluate whether Rituximab biosimilar maintains drug-free disease remission in patientswith steroid-dependent nephrotic syndrome for 12-24 months and verify its superiority vs. mycophenolate mofetil, the reference standard therapy. The investigators will compare the risk of relapse to test this hypothesis (primary outcome). Secondary objectives will include assessing short- and long-term side-effects and developing specific biomarkers of sensitivity to therapy. Patients will be recruited, treated and followed at IRCCS G Gaslini and IRCCS Bambino Gesù where laboratory studies will be performed at in-site facilities
|Condition or disease||Intervention/treatment||Phase|
|Nephrotic Syndrome Steroid-Dependent||Drug: Rituximab Biosimilar Drug: Mycophenolate Mofetil||Phase 2|
Idiopathic nephrotic syndrome (NS) is characterized by proteinuria and hypoalbuminemia associated with dyslipidemia and hypercoagulability. Oral corticosteroids are the cornerstone of therapy and induce disease remission in approximately 90% of cases. However, up to 85% of patients relapse and many develop steroid dependence (SDNS), requiring prolonged dose of steroids to maintain remission. Clinical practice guidelines (KDIGO) suggest using low-dose prednisone to maintain remission in SDNS and Mycophenolate Mofetil (MMF) or calcineurin inhibitors (CNI) as corticosteroid-sparing agents for children who develop steroid adverse effects. Given the toxicity of all these drugs (steroids, CNI and MMF), there is a need to investigate alternative options. Recent evidence supports the use of chimeric anti-CD20 monoclonal antibodies in simple SDNS (Rituximab, RTX).
The RTX4 trial is an open-label, two-parallel-arm, controlled and randomized clinical trial testing the superiority of RTX over MMF in maintaining steroid free disease remission in patients with SDNS.
Eligible participants are children and young adults (age between 3 and 24 years) with nephrotic syndrome who are dependent on prednisone 0.3-1mg/Kg/day and have received prednisone for at least six months before enrolment. Previous treatment with MMF will be allowed. All participants will enter a 45 days run-in period, during which children treated with steroids alone will start MMF 1,200 mg/1,73 sqm orally in 2 daily doses and will taper steroids after 15 days by 0.3 mg/kg per week until complete withdrawal. Patients already receiving MMF alone will continue the treatment. During the same period, instruction on urine collection and dipstick readings will be carefully reviewed and compliance assessed. After run-in period, children will be randomized to either the intervention arm (Rituximab, 375mg/m2) or the comparator arm (continuing or starting MMF). In the intervention arm, 1 month after infusion MMF will be decreased by 50% and withdrawn within 2 additional weeks, whereas MMF will be maintained in the comparator. All patients will be followed for up to 24 months. In case of relapses during this period (see outcome section for definition) patients will be treated with oral prednisone (60 mg/sqm day). Following remission, steroids will be maintained at the initial dose for 7 days and then tapered off by 0.3 mg/kg per week until complete withdrawal in patients of the MMF arm. Patients of the intervention arm will instead be treated with another infusion of RTX (same dose) immediately following steroid-induced remission. After infusion of RTX, steroids will be maintained at the initial dose for 7 days and then tapered off by 0.3 mg/kg per week until complete withdrawal. In this way relapsed patients in both arms will receive the same cumulative dose of prednisone. In case following relapse of proteinuria patients fail to respond to prednisone (they will terminate the study and be considered as treatment failure). The study allows drop-in from one arm to the other after 3 relapses (i.e., investigators will be allowed to use RTX in the comparator arm and vice versa MMF in intervention arm). The economic balance will be calculated on the basis of RTX doses needed to maintain remittance.
All patients will be followed for 24 months. In person visits will occure at enrollment, at T0 (infusion), after 1 month and every 3/6 months later.
The investigators are going to enroll 160 patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||The RTX4 trial is an open-label, two-parallel-arm, controlled and randomized clinical trial testing the superiority of RTX over MMF in maintaining steroid free disease remission in patients with SDNS|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of Chimeric Monoclonal Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome and Development of Cell Biomarkers Predicting Outcome. The RTX 4 Trial.|
|Actual Study Start Date :||July 1, 2019|
|Actual Primary Completion Date :||August 31, 2020|
|Actual Study Completion Date :||August 31, 2020|
Experimental: Rituximab biosimilar
Drug: Rituximab Biosimilar
for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
Active Comparator: Mycophenolate Mofetil
Drug Name: Mycophenolate Mofetil (MMF)
Drug: Mycophenolate Mofetil
1,200 mg/1,73 sqm orally divided in 2 daily doses
- Comparison between RTX and MMF, considering number of partecipants and relative relapses in the two cohorts [ Time Frame: 12-24 months ]The first expected result of the project is the demonstration that a single infusion of RTX is more likely than MMF to maintain remission of NS for 12-24 months in children with primary SDNS. In order to evaluate the remission, all the partecipats will document their proteinuria, relapse is defined by uPCR ≥2000 mg/g (≥ 200 mg/mmol) or > 3+ protein on urine dipstick for 3 consecutive days (KDIGO Clinical Practice Guideline for Glomerulonephritis, Kidney International Supplement, 2012 2, 163-171) and complete remission is defined by uPCR <200 mg/g (<20 mg/mmol) or o1+ of protein on urine dipstick for 3 consecutive days (KDIGO Clinical Practice Guideline for Glomerulonephritis, Kidney International Supplement, 2012 2, 163-171).
- RTX safety by evaluation and documentation of side effects [ Time Frame: 36 months ]A second result of the study will be based on the side-effects that RTX may induce: the investigators will record and measure frequency and severity of any treatment-related adverse events as assessed by CTCAE v4.0
- Biomarkers of response to RTX and evaluation of immune competence in patients treated with RTX vs. patients treated with MMF [ Time Frame: 36 months ]A third expected result is the identification of biomarkers of response to RTX and evaluation of immune competence in patients treated with RTX vs. patients treated with MMF. Mononuclear cells (PBMCs) will be characterized by flow cytometry. Samples for cell analysis will be obtained at the start of run-in (-45 days), at time 0 and after 3, 12 and 24 months; the same analysis will be performed in case of relapse. In parallel, total IgG, IgA and IgM levels will be assessed to evaluate the effect of B cell depletion on antibody production.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04402580
|IRCCS Istituto Giannina Gaslini|
|Genova, Italy, 16148|
|Principal Investigator:||Gianmarco Ghiggeri, MD||IRCCS Istituto Giannina Gaslini|